本文字数：2685，阅读时长大约4分钟 作者 | 第一财经 黄思瑜 2025.09. 25 因延期一年多交付安评研究报告，美迪西（688202.SH）全资子公司被告上法庭，遭索赔的金额达到 1.59亿元，是合同金额的28倍。 根据鸿绪生物声明，合同约定美迪西普亚应在8个月时间内完成并提供中文和英文两个版本的研究报 告，以确保鸿绪生物能够顺利获得中美临床试验批件。 "直至2022年12月底，美迪西（普亚）才将中文盖章纸质安评研究报告交付鸿绪生物，较合同约定时 间严重滞后。"鸿绪生物在声明中称，由于美迪西普亚在中文版安评研究报告定稿一年后，仍未提供 英文版安评研究报告，鸿绪生物于2023年12月向法院提起诉讼。2024年，美迪西普亚交付英文版安 评研究报告后，鸿绪生物撤诉。 报告延期交付过程中，双方是否进行了沟通，延期又有哪些原因？对此，吕涛说，双方有过沟通，鸿 绪生物一直在催美迪西普亚出报告，但对方没有明确回复延迟的原因，但是鸿绪生物也不好再找其他 公司，因为会额外增加资金成本，在当时情况下美迪西普亚能做出来是最好的。 起诉美迪西全资子公司的是鸿绪生物医药科技（北京）有限公司（下称"鸿绪生物"）。根据鸿绪生物 ...

双方各执一词，法庭见。 因延期一年多交付安评研究报告，美迪西（688202.SH）全资子公司被告上法庭，遭索赔的金额达到 1.59亿元，是合同金额的28倍。 起诉美迪西全资子公司的是鸿绪生物医药科技（北京）有限公司（下称"鸿绪生物"）。根据鸿绪生物近 期声明，该公司2020年12月委托美迪西子公司开展新药非临床安全性评价研究，并约定在8个月内交付 中英文两个版本研究报告，而后者不但全部延期一年以上才交付，也未通过国内和美国药监局审查，且 中文版报告之后找第三方CRO公司补充试验后，才获得临床试验批件。 "这是鸿绪生物GLP-1糖尿病药/减肥药项目临床前的一个研究工作，一般是对猴子、老鼠等动物进行实 验，评测安全性，医药公司拿到报告之后才能去申请进行Ⅰ期临床试验，对人体进行实验。"熟悉鸿绪 生物的知情人士吕涛对第一财经称。 此事源于2020年12月，鸿绪生物与美迪西普亚医药科技(上海)有限公司（下称"美迪西普亚"）签署了一 份《技术服务合同》，前者委托后者对I类生物技术药(多肽)进行非临床安全性评价研究，以支持中国国 家药品监督管理局（NMPA）和美国食品药品监督管理局（FDA）Ⅰ期临床试验申请。合同金额为 5 ...

Group 1 - The core revenue of the company for the first half of 2025 reached 375 million yuan, with new orders amounting to 532 million yuan, reflecting a year-on-year increase of 7.39% [1] - The total backlog of orders stood at 1.112 billion yuan, which is a 14.29% increase compared to the end of 2024 [1] - The company experienced growth across all business segments, with a combined year-on-year increase of 6.86% in new projects for IND and NDA applications [1] Group 2 - The company is a leading comprehensive R&D service provider in the biopharmaceutical non-clinical research sector, recognized for its international service capabilities [2] - As of June 30, 2025, the company has successfully assisted in over 200 innovative drug research services, including several groundbreaking therapies and products [2] - The strategic project in Nantong has been successfully implemented, covering an area of 24,000 square meters and featuring 130 international standard animal housing units, which will enhance the company's capacity and efficiency in innovative molecules and advanced therapies [2]

Core Viewpoint - Tiger Med voluntarily disclosed the acquisition of 56.37% stake in Japanese company MICRON, despite the transaction amount not meeting mandatory disclosure standards [2][5]. Group 1: Acquisition Details - Tiger Med's wholly-owned subsidiary, Tiger Med Japan, signed a share transfer agreement to purchase part of MICRON's shares for a total price of 484 million JPY, approximately 23.48 million CNY [5]. - Following the completion of this transfer, Tiger Med will hold 56.37% of MICRON [5]. - MICRON, established in 2005 and headquartered in Tokyo, specializes in medical imaging and clinical trial services, employing over 160 people and serving more than 250 clients [5]. Group 2: Financial Overview - As of May 31, 2025, MICRON's total assets were 781 million JPY, with a net asset value of -452 million JPY [6]. - For the period from January to May 2025, MICRON reported a main business revenue of 940 million JPY and a net loss of 67.05 million JPY [6]. Group 3: Strategic Implications - The acquisition is expected to leverage MICRON's strong foundation and customer resources in the Japanese market, facilitating Tiger Med's expansion in Japan and the Asia-Pacific region [6]. - The collaboration aims to enhance the integration of technology and talent, strengthening the competitive edge in medical imaging and clinical services, which is anticipated to positively impact the company's future operations [6]. Group 4: Market Reaction - Following the announcement, Tiger Med's stock price surged, with A-shares increasing by 8.8% and H-shares rising by 9.45% [6]. - As of July 29, the market capitalization of Tiger Med's A-shares reached 59.18 billion CNY [6]. Group 5: Recent Developments - Coincidentally, on July 28, Tiger Med announced that its actual controller, Cao Xiaochun, plans to reduce his holdings by up to 3 million shares within three months, potentially cashing out around 200 million CNY at current stock prices [9].